Sukarit_notes.md 1.2 KB

Summary

  • Thrombosis
  • Intravasal clot formation
  • Insufficient safety consideration by AMA
  • Dissaminated Intravascular Coagulation - exhaust clotting system
  • Intracranial/Cerebral blood clots
  • Cerebral Venous Thrombosis
  • Pfizer study suggests 52 persons under 55 would die from vaccination, when normal rate would be ~10

Clots

  • Variety of symptoms
  • Vaccines taken up by vessel wall (endothelial cells)
  • Spike presented at wall (facing bloodstream)
  • Spikes can activate platelets
  • Spike-presenting sites will be attacked by NK cells
  • Repair of vessel wall will also induce clotting

Pharmacokinetics

  • Normal infection has a progression along respiratory system
  • This means that the immunity will be dispersed accordingly (in spite of lymphocytes having to mature in thymus, it still is the difference when it comes to circulatory vs secretory)
  • If LNP enter bloostream, there's no way out - must come into contact with vessel wall
  • These will be the cells which take up the genes in quantity

Site behaviour

  • Spike protrudes along with waste product
  • Spike can induce platelets to activate
  • Lymphocyte notice waste signature and attack cell
  • Sites likely where blood flow is most sluggish - more time for uptake -